Sat.Mar 19, 2022 - Fri.Mar 25, 2022

article thumbnail

Data shows Netherlands best base for international pharmaceutical companies

Drug Discovery Today

The ranking was calculated on cost and time efficiencies and United States was shown to be the most efficient jurisdiction on speed of business whereas Brazil, South Korea and China scored less favorably

article thumbnail

2 Strategies to Grow Your Excipient Business by Tracking Drug Patents

Drug Patent Watch

Drugs contain ingredients with therapeutic activity, so-called “active ingredients” as well as inactive ingredients. These inactive ingredients, called excipients, are included in oral products for various reasons, such as to…. The post 2 Strategies to Grow Your Excipient Business by Tracking Drug Patents appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 105
article thumbnail

Warped Incentives Update: The Gross-to-Net Bubble Exceeded $200 Billion in 2021

Drug Channels

Time for Drug Channels Institute’s annual update on the gross-to-net bubble —the ever-growing dollar gap between sales at brand-name drugs' list prices and their sales at net prices after rebates and other reductions. We estimate that the gross-to-net bubble reached $204 billion for patent-protected brand-name drugs in 2021. If we include brand-name drugs that have lost patent protection and face competition from generic equivalents, the bubble was even higher, at $236 billion.

article thumbnail

Evusheld long-acting antibody combination recommended for approval in the EU for the pre-exposure prophylaxis (prevention) of COVID-19

The Pharma Data

AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination, has been recommended for marketing authorisation in the European Union (EU) for the pre-exposure prophylaxis (prevention) of COVID-19 in a broad population of adults and adolescents aged 12 years and older weighing at least 40 kg. People not adequately protected by a COVID-19 vaccine may particularly benefit from pre-exposure prophylaxis with Evusheld.

Vaccine 52
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

500 – and counting!

Sygnature Discovery

When DMPK scientist Lynette Ongeri joined Sygnature this month, she unknowingly helped us reach a landmark we couldn’t be prouder of… Sygnature Discovery – or Sygnature Chemical Services Ltd, as it was known then – opened its doors in 2004 with five colleagues. Sygnature’s first logo Led by founder Simon Hirst, this ambitious small Chemistry group hit the ground running, quickly developing strong relationships with customers and expanding into other scientific specialities like Computation

article thumbnail

DrugPatentWatch Week in Review

Drug Patent Watch

FEATURED ARTICLE Branded Generics Promise Profits for Drugmakers, Peace of Mind for Patients Developing nations offer welcoming and growing markets as Abbott focuses exclusively on reformulating and marketing off-patent medications…. The post DrugPatentWatch Week in Review appeared first on DrugPatentWatch - Make Better Decisions.

Marketing 102

More Trending

article thumbnail

WHO establishes the Global Centre for Traditional Medicine in India

The Pharma Data

Maximizing potential of traditional medicines through modern science and technology. The World Health Organization (WHO) and the Government of India today signed an agreement to establish the WHO Global Centre for Traditional Medicine. This global knowledge centre for traditional medicine, supported by an investment of USD 250 million from the Government of India, aims to harness the potential of traditional medicine from across the world through modern science and technology to improve the heal

article thumbnail

Waterfall or Agile: Wrong Question!

EG Life Sciences

Throughout the Biopharma industry, organizations are applying Agile principles and practices to get drugs to market faster and keep up with demands following the pandemic. Eliassen Group and EG Life Sciences have been working hand in hand with experts in many different fields – not just IT – to ensure that these organizations successfully achieve the benefits of enterprise agility.

Science 52
article thumbnail

Which pharmaceutical companies have the most drug patents in Slovakia?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most patents in Slovakia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Slovakia? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Federal Law Expressly Preempts State-Law Misbranding Claims Predicated on Labeling Statements Approved By A Federal Agency

Drug & Device Law

Today we report on Thornton v. Tyson Foods, Inc. , — F.4th —-, 2022 WL 727628 (10th Cir. 2022)—a favorable express-preemption decision under the Federal Meat Inspection Act (FMIA), 21 U.S.C. §§ 601–695, that is directly applicable to medical-device cases. Although decided under a different statute, Thornton makes clear that the FDCA bars state-law claims challenging labeling statements approved by the FDA through the premarket approval process—even if those statements are allegedly false and the

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Alpaca nanobodies potently neutralize SARS-CoV-2 variants

The Pharma Data

Researchers at Karolinska Institutet in Sweden have developed a novel strategy for identifying potent miniature antibodies, so-called nanobodies, against emerging SARS-CoV-2 variants. The approach led to the discovery of multiple nanobodies that in cell cultures and mice effectively blocked infection with different SARS-CoV-2 variants. The findings, which are described in the journals Nature Communications and Science Advances, could pave the way for new treatments against COVID-19. “With

article thumbnail

Which drugs have supplementary protection certificates in the most countries?

Drug Patent Watch

This chart shows the drugs with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the long…. The post Which drugs have supplementary protection certificates in the most countries? appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent for Zogenix Inc drug FINTEPLA

Drug Patent Watch

Annual Drug Patent Expirations for FINTEPLA Fintepla is a drug marketed by Zogenix Inc and is included in one NDA. It is available from one supplier. There are eleven patents…. The post New patent for Zogenix Inc drug FINTEPLA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent for Deciphera Pharms drug QINLOCK

Drug Patent Watch

Annual Drug Patent Expirations for QINLOCK Qinlock is a drug marketed by Deciphera Pharms and is included in one NDA. There are five patents protecting this drug. This drug has…. The post New patent for Deciphera Pharms drug QINLOCK appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

New patent for Strongbridge drug RECORLEV

Drug Patent Watch

Annual Drug Patent Expirations for RECORLEV Recorlev is a drug marketed by Strongbridge and is included in one NDA. There are five patents protecting this drug. This drug has twenty-seven…. The post New patent for Strongbridge drug RECORLEV appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Which pharmaceutical companies have the most SPCs in Romania?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Romania. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Romania? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Roche donates additional medicines and diagnostics for Ukraine

The Pharma Data

Roche today announced the donation of additional medicines and diagnostics to Ukraine. Beyond the already communicated 150,000 packs of an antibiotic medicine the new donation includes another 4,600 packs of specialized medicines for the treatment of influenza, rheumatoid arthritis, SMA and various cancers. We are also donating reagents and consumables for automatic testing of up to 120,000 blood donations and 31,000 units for diabetes management.

article thumbnail

Pfizer Announces Positive Top-Line Results for Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients

The Pharma Data

– ELEVATE 12 study met primary and key secondary endpoints of improving clinical remission at week 12 – – Safety profile consistent with previous Phase 2 studies – Pfizer Inc. (NYSE: PFE) today announced positive topline results from a Phase 3 study of etrasimod, an investigational, oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator in development for the treatment of moderately to severely active ulcerative colitis (UC).

Trials 52
article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

Learning from women’s experiences during childbirth to improve quality of care

The Pharma Data

A special supplement from WHO and HRP , newly published in BMJ Global Health , spotlights how women and their newborn babies are treated during childbirth and offers a path to improved facility-based care. More and more evidence showsthat women across the world face unacceptable mistreatment during childbirth. Women everywhere face violations of their rights – including rights to privacy, informed consent, and the right have a trusted companion of choice throughout childbirth. .

article thumbnail

Targeting a human protein may stop Ebola virus in its tracks

The Pharma Data

To treat Ebola virus infections, researchers are taking a close look at a key piece of the virus: polymerase. Polymerase is a viral protein that directs how Ebola virus replicates its genome as it infects new hosts. Drugs that target polymerase could potentially treat Ebola virus infections and save lives. Now scientists at La Jolla Institute for Immunology (LJI) and Scripps Research have found a promising strategy for stopping Ebola virus polymerase.

Virus 52
article thumbnail

Chemical found in leafy greens shown to slow growth of COVID-19 and common cold viruses

The Pharma Data

Researchers at Johns Hopkins Children’s Center report evidence from lab experiments that a chemical derived from a compound found abundantly in broccoli and other cruciferous plants may offer a potentially new and potent weapon against the viruses that cause COVID-19 and the common cold. COVID-19 has already killed more than 6 million people worldwide, and studies have shown that common colds cost an estimated economic loss of $25 billion in the U.S. alone each year.

Virus 52
article thumbnail

New patent expiration for Boehringer Ingelheim drug SPIRIVA

Drug Patent Watch

Annual Drug Patent Expirations for SPIRIVA Spiriva is a drug marketed by Boehringer Ingelheim and is included in two NDAs. It is available from two suppliers. There are sixteen patents…. The post New patent expiration for Boehringer Ingelheim drug SPIRIVA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent for Boehringer Ingelheim drug JARDIANCE

Drug Patent Watch

Annual Drug Patent Expirations for JARDIANCE Jardiance is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from four suppliers. There are seven patents…. The post New patent for Boehringer Ingelheim drug JARDIANCE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent for Pfizer drug XELJANZ XR

Drug Patent Watch

Annual Drug Patent Expirations for XELJANZ+XR Xeljanz Xr is a drug marketed by Pfizer and is included in one NDA. It is available from two suppliers. There are four patents…. The post New patent for Pfizer drug XELJANZ XR appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent for Genentech Inc drug GAVRETO

Drug Patent Watch

Annual Drug Patent Expirations for GAVRETO Gavreto is a drug marketed by Genentech Inc and is included in one NDA. It is available from one supplier. There is one patent…. The post New patent for Genentech Inc drug GAVRETO appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent for Genentech Inc drug ROZLYTREK

Drug Patent Watch

Annual Drug Patent Expirations for ROZLYTREK Rozlytrek is a drug marketed by Genentech Inc and is included in one NDA. It is available from one supplier. There are thirteen patents…. The post New patent for Genentech Inc drug ROZLYTREK appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Which pharmaceutical companies have the most SPCs in France?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in France. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in France? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

New patent for Genentech Inc drug COTELLIC

Drug Patent Watch

Annual Drug Patent Expirations for COTELLIC Cotellic is a drug marketed by Genentech Inc and is included in one NDA. It is available from one supplier. There are five patents…. The post New patent for Genentech Inc drug COTELLIC appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent expiration for Plx Pharma drug VAZALORE

Drug Patent Watch

Annual Drug Patent Expirations for VAZALORE Vazalore is a drug marketed by Plx Pharma and is included in one NDA. There are four patents protecting this drug. This drug has…. The post New patent expiration for Plx Pharma drug VAZALORE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Bristol Myers Squibb to Demonstrate the Strength of its Growing Cardiovascular Portfolio at the American College of Cardiology’s 71st Annual Scientific Session

The Pharma Data

New data, including two late-breaking clinical trial presentations on mavacamten and a new analysis of the GUARD-AF study, reinforce the company’s continued commitment to those living with cardiovascular disease. PRINCETON, N.J.–(BUSINESS WIRE)– Bristol Myers Squibb (NYSE: BMY) today announced that data from its cardiovascular portfolio will be presented at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22), taking place in Washington, DC, and virtually, fro

article thumbnail

Boehringer Ingelheim and the World Association for Buiatrics support outstanding research on ruminant animal health and well-being

The Pharma Data

Boehringer Ingelheim supports young scientists and veterinarians dedicated to ruminant health research Submissions for Ruminant Well-Being Awards and Gustav Rosenberger Memorial Fund grant open now. Boehringer Ingelheim, a global leader in animal health supports farmers and veterinarians worldwide in their work and promotes better farming practices to achieve long-term, positive impact not only in terms of animal health, but also in terms of well-being.

article thumbnail

Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations

The Pharma Data

Co-founded at Fred Hutchinson Cancer Research Center with Phil Greenberg, M.D., Aude Chapuis, M.D., and Tom Schmitt, Ph.D., and Vida Ventures along with serial entrepreneurs Arjun Goyal, M.D., M.Phil., and Jak Knowles, M.D./ Foundational cell therapy platform builds upon seminal work from co-founders, leveraging a T Cell Receptor (TCR) discovery engine and suite of synthetic biology components intending to develop potentially best-in-class therapies targeting oncogenic driver mutations like KRAS

article thumbnail

Pfizer to supply UNICEF up to 4 million treatment courses of novel COVID-19 oral treatment for low- and middle-income countries

The Pharma Data

Pfizer Inc. (NYSE: PFE) announced today an agreement with UNICEF to supply up to 4 million treatment courses of its COVID-19 oral treatment, PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets), to 95 low- and middle-income countries, pending authorization or approval. This includes all low- and lower-middle-income countries and some upper-middle-income countries in Sub-Saharan Africa as well as countries that have transitioned from lower-middle to upper-middle-income status in t